Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19877104rdf:typepubmed:Citationlld:pubmed
pubmed-article:19877104lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:19877104lifeskim:mentionsumls-concept:C0003873lld:lifeskim
pubmed-article:19877104lifeskim:mentionsumls-concept:C0025677lld:lifeskim
pubmed-article:19877104lifeskim:mentionsumls-concept:C0162579lld:lifeskim
pubmed-article:19877104lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:19877104lifeskim:mentionsumls-concept:C0205177lld:lifeskim
pubmed-article:19877104lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:19877104lifeskim:mentionsumls-concept:C1872109lld:lifeskim
pubmed-article:19877104lifeskim:mentionsumls-concept:C0728831lld:lifeskim
pubmed-article:19877104lifeskim:mentionsumls-concept:C0033269lld:lifeskim
pubmed-article:19877104pubmed:issue11lld:pubmed
pubmed-article:19877104pubmed:dateCreated2009-11-10lld:pubmed
pubmed-article:19877104pubmed:databankReferencehttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19877104pubmed:databankReferencehttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19877104pubmed:abstractTextTo assess the impact of certolizumab pegol (CZP), a novel PEGylated anti-tumor necrosis factor, in combination with methotrexate (MTX) on productivity outside and within the home, and on participation in family, social, and leisure activities in adult patients with rheumatoid arthritis (RA).lld:pubmed
pubmed-article:19877104pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19877104pubmed:languageenglld:pubmed
pubmed-article:19877104pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19877104pubmed:citationSubsetAIMlld:pubmed
pubmed-article:19877104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19877104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19877104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19877104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19877104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19877104pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19877104pubmed:statusMEDLINElld:pubmed
pubmed-article:19877104pubmed:monthNovlld:pubmed
pubmed-article:19877104pubmed:issn0004-3591lld:pubmed
pubmed-article:19877104pubmed:authorpubmed-author:van...lld:pubmed
pubmed-article:19877104pubmed:authorpubmed-author:StrandVibekeVlld:pubmed
pubmed-article:19877104pubmed:authorpubmed-author:SmolenJosef...lld:pubmed
pubmed-article:19877104pubmed:authorpubmed-author:EmeryPaulPlld:pubmed
pubmed-article:19877104pubmed:authorpubmed-author:KeystoneEdwar...lld:pubmed
pubmed-article:19877104pubmed:authorpubmed-author:KavanaughArth...lld:pubmed
pubmed-article:19877104pubmed:authorpubmed-author:PurcaruOanaOlld:pubmed
pubmed-article:19877104pubmed:authorpubmed-author:RichardLanceLlld:pubmed
pubmed-article:19877104pubmed:issnTypePrintlld:pubmed
pubmed-article:19877104pubmed:day15lld:pubmed
pubmed-article:19877104pubmed:volume61lld:pubmed
pubmed-article:19877104pubmed:ownerNLMlld:pubmed
pubmed-article:19877104pubmed:authorsCompleteYlld:pubmed
pubmed-article:19877104pubmed:pagination1592-600lld:pubmed
pubmed-article:19877104pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:19877104pubmed:meshHeadingpubmed-meshheading:19877104...lld:pubmed
pubmed-article:19877104pubmed:meshHeadingpubmed-meshheading:19877104...lld:pubmed
pubmed-article:19877104pubmed:meshHeadingpubmed-meshheading:19877104...lld:pubmed
pubmed-article:19877104pubmed:meshHeadingpubmed-meshheading:19877104...lld:pubmed
pubmed-article:19877104pubmed:meshHeadingpubmed-meshheading:19877104...lld:pubmed
pubmed-article:19877104pubmed:meshHeadingpubmed-meshheading:19877104...lld:pubmed
pubmed-article:19877104pubmed:meshHeadingpubmed-meshheading:19877104...lld:pubmed
pubmed-article:19877104pubmed:meshHeadingpubmed-meshheading:19877104...lld:pubmed
pubmed-article:19877104pubmed:meshHeadingpubmed-meshheading:19877104...lld:pubmed
pubmed-article:19877104pubmed:meshHeadingpubmed-meshheading:19877104...lld:pubmed
pubmed-article:19877104pubmed:meshHeadingpubmed-meshheading:19877104...lld:pubmed
pubmed-article:19877104pubmed:meshHeadingpubmed-meshheading:19877104...lld:pubmed
pubmed-article:19877104pubmed:meshHeadingpubmed-meshheading:19877104...lld:pubmed
pubmed-article:19877104pubmed:meshHeadingpubmed-meshheading:19877104...lld:pubmed
pubmed-article:19877104pubmed:meshHeadingpubmed-meshheading:19877104...lld:pubmed
pubmed-article:19877104pubmed:meshHeadingpubmed-meshheading:19877104...lld:pubmed
pubmed-article:19877104pubmed:meshHeadingpubmed-meshheading:19877104...lld:pubmed
pubmed-article:19877104pubmed:meshHeadingpubmed-meshheading:19877104...lld:pubmed
pubmed-article:19877104pubmed:year2009lld:pubmed
pubmed-article:19877104pubmed:articleTitleEffect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis.lld:pubmed
pubmed-article:19877104pubmed:affiliationCenter for Innovative Therapy, University of California, San Diego, Division of Rheumatology, Allergy and Immunology, 9500 Gilman Drive, Mail Code 0943, La Jolla, CA 92093-0943, USA. akavanaugh@ucsd.edulld:pubmed
pubmed-article:19877104pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19877104pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:19877104pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:19877104pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:19877104pubmed:publicationTypeClinical Trial, Phase IIIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19877104lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19877104lld:pubmed